Program
CHF10073
A development code. Also written as “CHF10073 low dose”, “CHF10073 high dose” and “CHF10073 (Part 1 - SAD)”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis, led by Chiesi Farmaceutici.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceutici | 21 open or running | phase 1since Nov 26, 2024 | Nov 26, 2024 | Aug 2027phase 1 · NCT07876284 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 26, 2024First study: phase 1 study in Pulmonary FibrosisFirst studyNCT06746064 · 155 enrolled · Belgium
- Oct 9, 2026Phase 1 study in Idiopathic Pulmonary FibrosisNCT07876284 · 18 planned
Ahead
- Aug 2027Primary completion: phase 1 study in Idiopathic Pulmonary FibrosisNCT07876284
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07876284Idiopathic Pulmonary Fibrosis | 1 | Not yet recruiting | Aug 2027 | 18 |
| NCT06746064Pulmonary Fibrosis · Belgium | 1 | Completed | Feb 4, 2026 | 155 |
How it is read
Names in the registry
- “CHF10073 low dose”, 1 entry
- “CHF10073 high dose”, 1 entry
- “CHF10073 (Part 1 - SAD)”, 1 entry
- “CHF10073 (Part 2 - MAD)”, 1 entry
- “CHF10073 (Part 3)”, 1 entry
Codes read as this program: CHF10073.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
- Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.